Snapshot: Despite Advances in RNAi Science, the Field Sees Departures of Would-Be Rx Developers
August 20, 2009
Snapshot: Despite Advances in RNAi Science, the Field Sees Departures of Would-Be Rx Developers
While most companies working in the RNAi drugs field have been able to secure the money needed to maintain operations, a number of players in the space have bowed out under unfavorable circumstances.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- RXi’s CEO Resigns as Company Looks to Clinic, Industry Partnerships
November 12, 2009 / Gene Silencing News - Galena Faces Second Investor Lawsuit over Planned RXi Spin Out
January 19, 2012 / Gene Silencing News - Maturing RNAi Industry Suggests It Spends Time in Court and in the Lab
August 25, 2011 / Gene Silencing News - Benitec Says USPTO Poised to Finalize Validity Ruling for Key Patent
February 17, 2011 / Gene Silencing News - Re-Exam of Benitec US Patent Ends, Company Hits Opposition in UK
November 11, 2010 / Gene Silencing News